Literature DB >> 22670171

Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.

Valerie L Miller1, Hsueh-Kung Lin, Paari Murugan, Michael Fan, Trevor M Penning, Lacy S Brame, Qing Yang, Kar-Ming Fung.   

Abstract

Human aldo-keto reductase family 1 member C3 (AKR1C3) was initially identified as a critical enzyme in reducing 5α-dihydrotestosterone (5α-DHT) to 5α-androstane-3α,17β-diol (3α-diol) and oxidizing 3α-diol to androsterone. Based on these enzymatic activities, AKR1C3 was originally named type 2 3α-hydroxysteroid dehydrogenase (HSD)/type 5 17β-HSD. Additionally, AKR1C3 was demonstrated to be capable of metabolizing other steroids including estrogen and progesterone. Subsequently, AKR1C3 was shown to possess 11-ketoprostaglandin reductase activity in metabolizing prostaglandins and dihydrodiol dehydrogenase x (DDx) activity in metabolizing xenobiotics. Tissue distribution of AKR1C3 has been detected in both sex hormone-dependent organs such as the testis, breast, endometrium, and prostate as well as sex hormone-independent organs including the kidney and urothelium. Although prominent expression of AKR1C isozymes has been reported in human non-small cell lung carcinoma (NSCLC), the expression of AKR1C3 in small cell carcinoma of the lung has not been described. Also, the expression of AKR1C3 in normal lung has not been described. In this study, we demonstrated strong AKR1C3 immunoreactivity in bronchial epithelium but not in bronchial glands or alveolar pneumocytes. Strong AKR1C3 immunoreactivity was also demonstrated in columnar epithelium but only weak immunoreactivity in squamous epithelium of the gastrointestinal junction. Although AKR1C3 immunoreactivity was absent in small cell carcinoma of the lung, positive AKR1C3 immunoreactivity was extensively present in both adenocarcinoma and squamous cell carcinoma arising from the lung and the gastroesophageal junction. AKR1C3 may serve as an adjunct marker for differentiating small cell carcinoma from NSCLC. However, roles of AKR1C3 in adenocarcinoma, squamous cell carcinoma, and small cell carcinoma pathogenesis require further studies.

Entities:  

Keywords:  AKR1C3; adenocarcinoma; esophagus; gastroesophageal junction; lung; non-small cell carcinoma; small cell carcinoma; squamous cell carcinoma; stomach

Mesh:

Substances:

Year:  2012        PMID: 22670171      PMCID: PMC3365826     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  45 in total

Review 1.  Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review.

Authors:  Weiling Xue; David Warshawsky
Journal:  Toxicol Appl Pharmacol       Date:  2005-01-08       Impact factor: 4.219

2.  Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma.

Authors:  Kuan-Chih Chow; Mei-Pao Lu; Meng-Tse Wu
Journal:  J Dermatol Sci       Date:  2005-12-19       Impact factor: 4.563

Review 3.  Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones.

Authors:  T M Penning; M E Burczynski; C F Hung; K D McCoull; N T Palackal; L S Tsuruda
Journal:  Chem Res Toxicol       Date:  1999-01       Impact factor: 3.739

4.  The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers.

Authors:  Chen-Tu Wu; Yih-Leong Chang; Jin-Yuan Shih; Yung-Chie Lee
Journal:  J Thorac Cardiovasc Surg       Date:  2005-10       Impact factor: 5.209

5.  AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.

Authors:  Tea Lanisnik Rizner; Tina Smuc; Ruth Rupreht; Jasna Sinkovec; Trevor M Penning
Journal:  Mol Cell Endocrinol       Date:  2005-12-09       Impact factor: 4.102

6.  In situ androgen producing enzymes in human prostate cancer.

Authors:  Yasuhiro Nakamura; Takashi Suzuki; Masao Nakabayashi; Mareyuki Endoh; Kazuhiro Sakamoto; Yoshiki Mikami; Takuya Moriya; Akihiro Ito; Shoki Takahashi; Shogo Yamada; Yoichi Arai; Hironobu Sasano
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

7.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.

Authors:  Hsueh-Kung Lin; Stephan Steckelbroeck; Kar-Ming Fung; Amy N Jones; Trevor M Penning
Journal:  Steroids       Date:  2004-12       Impact factor: 2.668

8.  Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.

Authors:  M E Burczynski; H K Lin; T M Penning
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Oxidative DNA damage induced by benz[a]anthracene dihydrodiols in the presence of dihydrodiol dehydrogenase.

Authors:  Kazuharu Seike; Mariko Murata; Kazutaka Hirakawa; Yoshihiro Deyashiki; Shosuke Kawanishi
Journal:  Chem Res Toxicol       Date:  2004-11       Impact factor: 3.739

View more
  15 in total

Review 1.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

2.  Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.

Authors:  Alon Mantel; Amanda Carpenter-Mendini; JoAnne VanBuskirk; Alice P Pentland
Journal:  Exp Dermatol       Date:  2014-07-16       Impact factor: 3.960

3.  Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.

Authors:  Theodore S Chang; Hsueh-Kung Lin; Kyle A Rogers; Lacy S Brame; Matthew M Yeh; Qing Yang; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

4.  OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Authors:  Kathryn Evans; JianXin Duan; Tara Pritchard; Connor D Jones; Lisa McDermott; Zhaohui Gu; Cara E Toscan; Narimanne El-Zein; Chelsea Mayoh; Stephen W Erickson; Yuelong Guo; Fanying Meng; Donald Jung; Komal S Rathi; Kathryn G Roberts; Charles G Mullighan; Chi-Sheng Shia; Tillman Pearce; Beverly A Teicher; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2019-04-23       Impact factor: 13.801

5.  Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.

Authors:  Óscar Aguilera; José Manuel González-Sancho; Sandra Zazo; Raúl Rincón; Agustín F Fernández; Olga Tapia; Francesc Canals; Beatriz Morte; Vincenzo Calvanese; José L Orgaz; Núria Niell; Susana Aguilar; José M Freije; Osvaldo Graña; David G Pisano; Aurea Borrero; Javier Martínez-Useros; Benilde Jiménez; Mario F Fraga; Jesús García-Foncillas; Carlos López-Otín; Miguel Lafarga; Federico Rojo; Alberto Muñoz
Journal:  Oncotarget       Date:  2015-03-20

6.  Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.

Authors:  Johanna Eriksson; Vadim Le Joncour; Pirjo Nummela; Tiina Jahkola; Susanna Virolainen; Pirjo Laakkonen; Olli Saksela; Erkki Hölttä
Journal:  Oncotarget       Date:  2016-03-22

7.  Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.

Authors:  Chiaki Nakarai; Kayo Osawa; Minami Akiyama; Nagahide Matsubara; Hiroki Ikeuchi; Tomoki Yamano; Seiichi Hirota; Naohiro Tomita; Makoto Usami; Yoshiaki Kido
Journal:  Clin Exp Med       Date:  2014-06-17       Impact factor: 3.984

8.  AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.

Authors:  Jing Zhao; Yang Xiang; Changji Xiao; Peng Guo; Dan Wang; Ying Liu; Yun Shen
Journal:  Int J Med Sci       Date:  2014-08-13       Impact factor: 3.738

9.  Quantitative evaluation of aldo-keto reductase expression in hepatocellular carcinoma (HCC) cell lines.

Authors:  Lei Yang; Ju Zhang; Shenyan Zhang; Weiwei Dong; Xiaomin Lou; Siqi Liu
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-04-11       Impact factor: 7.691

10.  Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.

Authors:  Lin Wang; Xiaozhong Li; Louxin Zhang; Qiang Gao
Journal:  BMC Cancer       Date:  2017-08-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.